Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone hydrochloride liposome + enlonstobart in relapsed/refractory peripheral T‑cell lymphoma
ChiCTR2500111610Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone and PBI-1308 in peripheral T-cell lymphoma (PTCL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Dose-limiting toxicities (DLTs), Recommended Phase II Dose (RP2D) and 1 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
mitoxantronePBI-1308
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2500111610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111610.